-
Targeted literature review of the burden of extraintestinal pathogenic Escherichia Coli among elderly patients in Asia Pacific regions
Author: Ohmagari, Norio; Choi, Won Suk; Tang, Hung-Jen; Atanasov, Petar; Jiang, Xiaobin; Pastor, Luis Hernandez; Nakayama, Yoshikazu; Chiang, Jason; Lim, Kyunghwa; Nievera, Maria Carmen
Journal: JOURNAL OF MEDICAL ECONOMICS. 2023; Vol. 26, Issue 1, pp. 168-178. DOI: 10.1080/13696998.2023.2169447
-
Evaluation of health economic impact of initial diagnostic modality selection for colorectal cancer liver metastases in suspected patients in China, Japan and the USA
Author: Blankenburg, Michael; Elhamamy, Mostafa; Zhang, Diana; Fujikawa, Naoto; Corbin, Alice; Jin, Guanyi; Harris, James; Knobloch, Gesine
Journal: JOURNAL OF MEDICAL ECONOMICS. 2023; Vol. 26, Issue 1, pp. 219-232. DOI: 10.1080/13696998.2023.2173436
-
Does an economic incentive affect provider behavior? Evidence from a field experiment on different payment mechanisms.
Author: Xi X1, Wang E1, Lu Q1, Chen P1, Wo T1, Tang K1.
Journal: J Med Econ. 2019 Jan;22(1):35-44. doi: 10.1080/13696998.2018.1539399. Epub 2018 Nov 15.
-
Constructing a value-based healthcare system for hypertensive patients through changing payment mode: evidence from a comparative study in rural China.
Author: Miao Y1,2, Yuan X3, Gu J1, Zhang L4, He R4, Sandeep S4, Wu J5.
Journal: J Med Econ. 2019 Mar;22(3):245-251. doi: 10.1080/13696998.2018.1558864. Epub 2019 Jan 17.
-
Real-world evidence of improved healthcare utilization in patients with schizophrenia or schizoaffective disorder after early treatment of paliperidone palmitate once-monthly treatment in Hong Kong.
Author: Choon JWY1, Wu DBC1,2, Chong HY1, Lo WTL3, Chong CSY3, Chung WS4, Chui EMC5, Tomlinson B6, Lee VWY7, Lee SC6, Lee KKC1.
Journal: J Med Econ. 2019 Mar;22(3):273-279. doi: 10.1080/13696998.2018.1560749. Epub 2019 Jan 14.
-
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Author: Liao W1,2, Huang J1,2, Hutton D3, Li Q1,2.
Journal: J Med Econ. 2019 Apr;22(4):344-349. doi: 10.1080/13696998.2019.1570221. Epub 2019 Feb 6.
-
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Author: Cai X1, Shi L2, Yang W1, Gu S3, Chen Y4, Nie L5, Ji L1.
Journal: J Med Econ. 2019 Apr;22(4):336-343. doi: 10.1080/13696998.2019.1570220. Epub 2019 Feb 4.
-
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Author: Zhao J1, Jiang K2, Li Q3, Zhang Y4, Cheng Y4, Lin Z5, Xuan J6.
Journal: J Med Econ. 2019 May;22(5):439-446. doi: 10.1080/13696998.2019.1580714. Epub 2019 Mar 5.